Slingshot members are tracking this event:
Aimmune (AIMT) Will Begin Enrollment for RAMSES Trial Designed to Build Real-World Experience with AR101 in Desensitization of Peanut Allergies in the Q2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
May 11, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Ramses Trial, Real-world Experience, Ar101, Peanut Allergies, Desensitization Of Peanut Allergies